Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Update on ORACLE
December 2018
SHARING OPTIONS:

BOULDER, Colo.—Biodesix’s observational registry study evaluating how BDX-XL2 affects physicians’ decision in routine clinical use (ORACLE) is now up to 10 sites across the United States. BDX-XL2, a noninvasive test that can determine whether lung nodules are cancerous or benign, screens blood samples by looking at plasma proteins together with clinical risk factors of lung cancer. Data for the test so far indicate that it could reduce unnecessary procedures by 40 percent by identifying benign nodules, consequently also reducing cost of care and patient anxiety. In the previous PANOPTIC trial, BDX-XL2 identified likely benign nodules with 97-percent sensitivity and 98-percent high negative predictive value.
 
“The ORACLE study is critical to understanding how BDX-XL2 impacts treatment decisions in a real-world environment, and a top priority for Biodesix,” said David Brunel, CEO of Biodesix. “We are committed to providing tools to physicians and patients across the continuum of lung cancer care.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.